Background
Methods
Search strategy and inclusion criteria
Study selection and quality assessment
Statistical analysis
Results
Literature search
Study characteristics and quality appraisal
Author (year) | Design | No. of patients | Age (year) | Detection method | Endpoint | Source of HR | Adjusted covariates | Follow-up |
---|---|---|---|---|---|---|---|---|
Knechtli et al. (1998) | Retrospective | 64 | 1.3–17 | PCR IG/TCR | 2-year EFS | Multivariate analysis | Philadelphia chromosome positive, pre-BMT relapse | Median: 35 months |
Bader et al. (2002) | Retrospective | 41 | 1.5–17.8 | PCR IG/TCR | 5-year EFS | KM curve | NA | Median: 5.75 years |
Sramkova et al. (2007) | Prospective | 36 | 1.1–19 | PCR IG/TCR | 4-year EFS | KM curve | NA | Median: 26 months |
Spinelli et al. (2007) | Prospective | 37 | 18–63 | PCR IG/TCR, or PCR fusion transcript | 3-year CIR, 3-year OS | KM curve | NA | Median: 23 months |
Bader et al. (2009) | Prospective | 91 | 3–22.6 | PCR IG/TCR | 4-year CIR; 4-year EFS | Multivariate analysis | Sex, age at relapse, remission status, time point of relapse, immunophenotype, site of relapse, stem-cell donor, T-cell depletion, time to transplantation, GVHD, MRD load before stem-cell transplantation | Median: 3.4 years |
Elorza et al. (2010) | Prospective | 31 | 0.8–12 | FC | 2-year EFS | KM curve | NA | Median: 9 months |
Lankester et al. (2010) | Prospective | 48 | Mean: 8 | PCR IG/TCR | 5-year CIR, 5-year EFS | KM curve | NA | Median 61.5 months |
Doney et al. (2011) | Retrospective | 161 | 18–62 | FC | 5-year CIR, 5-year RFS | Multivariate analysis | Disease status, year of transplantation, CMV serology mismatch | NA |
Bachanova et al. (2012) | Prospective | 86 | 1–63 | FC | 2-year CIR, 3-year DFS, 3-year OS | Multivariate analysis | Disease status, ALL subtype, sex, time from diagnosis to transplantation, CMV status | Median 3.9 years |
Ruggeri et al. (2012) | Retrospective | 170 | < 1–17 | PCR IG/TCR, or fusion transcripts | 4-year CIR; 4-year LFS, 4-year OS, 4-year NRM | Multivariate analysis | Age, median year of transplant, cytogenetic risk group, TBI-based conditioning regimen, number of HLA disparities | Median: 48 months |
Mizuta et al. (2012) | Prospective | 100 | 15–64 | PCR BCR-ABL | 3-year CIR, 3-year OS, 3-year DFS, 3-year NRM | Multivariate analysis | Age, donor status, chromosome abnormality, stem-cell source, performance status, BCR-ABL subtype, WBC, CD20 | Median: 31 months |
Sanchez-Garcia et al. (2013) | Retrospective | 102 | Mixed | FC | 5-year EFS, 5-year OS, 5-year RFS | Multivariate analysis | Age, disease status, stem-cell source, time from onset to HSCT, GVHD | Median: 60.8 months |
Balduzzi et al. (2014) | Prospective | 82 | < 1–20 | PCR IG/TCR | 5-year CIR, 5-year EFS | Multivariate analysis | Disease status, donor type, HLA compatibility, GVHD | Median 4.9 years |
Gandemer et al. (2014) | Prospective | 122 | ≤18 | PCR IG/TCR | 5-year CIR, DFS, OS | Multivariate analysis | Sex, antithymocyte globulins, CNS location, risk stratification | Median: 34.8 months |
Tucunduva et al. (2014) | Retrospective | 98 | 18–66 | PCR or FC BCR-ABL | 3-year CIR, 3-year LFS | Multivariate analysis | Age, sex, cytomegalovirus, disease status, transplantation method, conditioning, antithymocyte globulin, use of TKI, graft | Median: 36 months |
Logan et al. (2014) | Retrospective | 29 | 16–67 | PCR | DFS | KM curve | NA | Minimum: 3 years |
Zhou et al. (2014) | Retrospective | 149 | 18–70 | FC | 2-year OS, 2-year PFS | Multivariate analysis | Age, disease status, allotype, cell type | NA |
Bar et al. (2014) | Retrospective | 160 | 0.6–62 | FC | 3-year CIR, 3-year OS | Univariate analysis | None | Median: 40.6 months |
Bader et al. (2015) | Prospective | 113 | 0–18 | PCR IG/TCR | 3-year CIR, 3-year EFS, 3-year NRM | Multivariate analysis | Disease status, immunophenotype, time of relapse, T-cell depletion | Range: 3.4–6.5 years |
Sutton et al. (2015) | Prospective | 81 | < 18 | PCR IG/TCR | 5-year CIR, 5-year LFS, 5-year OS | Multivariate analysis | Sex, age, T-ALL, BCR-ABL1, hyperdiploidy > 50 or ETV6-RUNX1, BCP-other, IKZF1 mutation status, CR > 1, MSD, cord blood donor, mitoxantrone chemotherapy, TBI CY TT conditioning, in vitro T-cell depletion, ATG, GVHD | Median: 4.8 years |
Dh’edin et al. (2016) | Prospective | 522 | 15–55 | PCR IG/TCR | 3-year RFS, 3-year OS | KM curve | NA | Median: 3.5 years |
Relapse
Subgroups | No. of studies | HR (95% CI) | I2 (P value) |
---|---|---|---|
Population | |||
Children | 5 | 3.30 (1.48–7.36) | 73.1% (0.01) |
Adult | 4 | 2.90 (1.85–4.57) | 8.5% (0.35) |
Design | |||
Prospective | 7 | 4.21 (1.93–9.16) | 62.2% (0.01) |
Retrospective | 5 | 2.73 (1.96–3.79) | 7.1% (0.37) |
Region | |||
Europe | 7 | 3.21 (1.80–5.71) | 61.3% (0.02) |
USA | 4 | 3.27 (2.00–5.36) | 24.6% (0.26) |
Asia | 1 | 7.34 (0.54–99.59) | – |
Detection method | |||
PCR | 7 | 3.82 (1.94–7.53) | 62.0% (0.02) |
FC | 4 | 3.10 (1.92–5.02) | 17.0% (0.31) |
Adjustment | |||
Adjusted | 7 | 3.24 (2.10–5.00) | 32.8% (0.18) |
Crude | 5 | 3.43 (1.59–7.38) | 64.6% (0.02) |
Competing risk framework | |||
Yes | 10 | 2.96 (2.22–3.96) | 52.9%(0.02) |
No | 2 | 2.40(1.45–3.98) | 0.0 (0.39) |
RFS
Subgroups | No. of studies | HR (95% CI) | I2 (P value) |
---|---|---|---|
Population | |||
Children | 3 | 3.22 (1.68–6.18) | 57.6% (0.10) |
Adult | 4 | 1.69 (1.02–2.80) | 69.5% (0.02) |
Design | |||
Prospective | 5 | 2.37 (1.12–5.01) | 77.7% (< 0.01) |
Retrospective | 5 | 2.71 (1.58–4.64) | 73.5% (< 0.01) |
Region | |||
Europe | 5 | 2.38 (1.26–4.50) | 83.5% (< 0.01) |
USA | 3 | 2.87 (1.35–6.10) | 56.7% (0.10) |
Asia | 2 | 2.61 (0.66–10.40) | 75.6% (0.04) |
Detection method | |||
PCR | 5 | 2.09 (1.07–4.08) | 75.3% (< 0.01) |
FC | 4 | 3.58 (1.73–7.40) | 73.8% (< 0.01) |
Adjustment | |||
Adjusted | 7 | 2.50 (1.64–3.82) | 64.4% (0.01) |
Crude | 3 | 2.93 (0.81–10.64) | 86.3% (< 0.01) |
EFS
Subgroups | No. of studies | HR (95% CI) | I2 (P value) |
---|---|---|---|
Population | |||
Children | 6 | 5.62 (3.75–8.42) | 3.2% (0.40) |
Mixed adult and children | 2 | 3.60 (1.72–7.51) | 65.2% (0.09) |
Design | |||
Prospective | 5 | 5.33 (2.88–9.86) | 57.6% (0.05) |
Retrospective | 3 | 4.59 (2.89–7.27) | 0 (0.73) |
Detection method | |||
PCR | 6 | 4.97 (2.93–8.44) | 49.2% (0.08) |
FC | 2 | 4.77 (3.31–6.87) | 0 (0.70) |
Adjustment | |||
Adjusted | 4 | 4.56 (2.64–7.88) | 48.9% (0.12) |
Crude | 4 | 5.18 (2.94–9.11) | 24.4% (0.27) |
OS
Subgroups | No. of studies | HR (95% CI) | I2 (P value) |
---|---|---|---|
Population | |||
Adult | 4 | 1.15 (0.86–1.53) | 0 (0.73) |
Children | 3 | 2.40 (1.49–3.89) | 37.7% (0.20) |
Mixed adult and children | 3 | 3.06 (1.98–4.70) | 32.1% (0.23) |
Design | |||
Prospective | 6 | 1.68 (1.02–2.77) | 60.1% (0.03) |
Retrospective | 4 | 2.37 (1.55–3.63) | 64.8% (0.04) |
Region | |||
Europe | 5 | 2.05 (1.10–3.80) | 83.0% (< 0.01) |
USA | 3 | 2.10 (1.50–2.94) | 1.8% (0.36) |
Asia | 2 | 1.89 (0.99–3.62) | 0 (0.32) |
Detection method | |||
PCR | 6 | 1.65 (1.07–2.55) | 61.5% (0.02) |
FC | 4 | 2.53 (1.58–4.04) | 58.1% (0.07) |
Adjustment | |||
Adjusted | 4 | 2.58 (1.27–5.26) | 71.1% (0.02) |
Crude | 6 | 1.70 (1.18–2.44) | 58.7% (0.03) |